Long-term systemic neutralization of IL-1β by Canakinumab may increase the risk of serious upper respiratory tract infections, gastrointestinal disorders and vertigo, and decrease the quality of life of both patients and informal caregivers2,9,10,29. Here, IL1B is linked to digestive system disorder.